Journal of Bone and Mineral Metabolism

, Volume 31, Issue 5, pp 544–550

Number and severity of prevalent vertebral fractures and the risk of subsequent vertebral fractures in Japanese women with osteoporosis: results from the minodronate trial

  • Hiroshi Hagino
  • Masataka Shiraki
  • Masao Fukunaga
  • Tetsuo Nakano
  • Kunio Takaoka
  • Yasuo Ohashi
  • Toshitaka Nakamura
  • Toshio Matsumoto
Original Article


The aim was to evaluate the risk of new vertebral fractures with the increasing number and severity of prevalent vertebral fractures in women who received placebo or minodronate in a post hoc analysis of a 2-year randomized, double-blind, placebo-controlled study. The subjects were women aged 55–80 years old with 1–5 fragility fractures between the T4 and L4 vertebrae and bone mineral density <80 % of the young adult mean. A total of 704 subjects were randomized to take minodronate 1 mg (n = 359) or placebo (n = 345) once a day for 24 months. In the placebo group, the risk of incident vertebral fractures during the 2-year observational period was significantly related to the number and severity of prevalent vertebral fractures at baseline. The number of prevalent vertebral fractures was an independent risk factor for incident vertebral fracture in multivariate analysis. The relative risk reductions of vertebral fractures by minodronate treatment were 45.2, 61.1, and 64.2 % for patients with 1, 2, and ≥3 prevalent vertebral fractures, respectively, and 87.8, 64.6, and 50.1 % for patients with mild, moderate, and severe prevalent vertebral fractures, respectively. In conclusion, the number of prevalent vertebral fractures is an independent risk factor for incident vertebral fracture and minodronate reduces the fracture risk even in patients at a higher risk for fracture.


Osteoporosis Bisphosphonate Minodronate Fracture prevention 


  1. 1.
    Lindsay R, Silverman SL, Cooper C, Hanley DA, Barton I, Broy SB, Licata A, Benhamou L, Geusens P, Flowers K, Stracke H, Seeman E (2001) Risk of new vertebral fracture in the year following a fracture. JAMA 285:320–323PubMedCrossRefGoogle Scholar
  2. 2.
    Delmas PD, Genant HK, Crans GG, Stock JL, Wong M, Siris E, Adachi JD (2003) Severity of prevalent vertebral fractures and the risk of subsequent vertebral and nonvertebral fractures: results from the MORE trial. Bone 33:522–532PubMedCrossRefGoogle Scholar
  3. 3.
    Gallagher JC, Genant HK, Crans GG, Vargas SJ, Krege JH (2005) Teriparatide reduces the fracture risk associated with increasing number and severity of osteoporotic fractures. J Clin Endocrinol Metab 90:1583–1587PubMedCrossRefGoogle Scholar
  4. 4.
    Roux C, Fechtenbaum J, Kolta S, Briot K, Girard M (2007) Mild prevalent and incident vertebral fractures are risk factors for new fractures. Osteoporos Int 18:1617–1624PubMedCrossRefGoogle Scholar
  5. 5.
    Genant HK, Siris E, Crans GG, Desaiah D, Krege JH (2005) Reduction in vertebral fracture risk in teriparatide-treated postmenopausal women as assessed by spinal deformity index. Bone 37:170–174PubMedCrossRefGoogle Scholar
  6. 6.
    Kadowaki E, Tamaki J, Iki M, Sato Y, Chiba Y, Kajita E, Kagamimori S, Kagawa Y, Yoneshima H (2010) Prevalent vertebral deformity independently increases incident vertebral fracture risk in middle-aged and elderly Japanese women: the Japanese Population-based Osteoporosis (JPOS) Cohort Study. Osteoporos Int 21:1513–1522PubMedCrossRefGoogle Scholar
  7. 7.
    Hagino H, Yamamoto K, Ohshiro H, Nakamura T, Kishimoto H, Nose T (1999) Changing incidence of hip, distal radius, and proximal humerus fractures in Tottori Prefecture, Japan. Bone 24:265–270PubMedCrossRefGoogle Scholar
  8. 8.
    Hagino H (2012) Fragility fracture prevention: review from a Japanese perspective. Yonago Acta Medica 55:21–28PubMedGoogle Scholar
  9. 9.
    Fujiwara S, Kasagi F, Masunari N, Naito K, Suzuki G, Fukunaga M (2003) Fracture prediction from bone mineral density in Japanese men and women. J Bone Miner Res 18:1547–1553PubMedCrossRefGoogle Scholar
  10. 10.
    Ross PD, Fujiwara S, Huang C, Davis JW, Epstein RS, Wasnich RD, Kodama K, Melton LJ 3rd (1995) Vertebral fracture prevalence in women in Hiroshima compared to Caucasians or Japanese in the US. Int J Epidemiol 24:1171–1177PubMedCrossRefGoogle Scholar
  11. 11.
    Yoshimura N, Kinoshita H, Danjoh S (1995) Prevalence of vertebral fractures in a rural Japanese population. J Epidemiol 5:171–175CrossRefGoogle Scholar
  12. 12.
    Kitazawa A, Kushida K, Yamazaki K, Inoue T (2001) Prevalence of vertebral fractures in a population-based sample in Japan. J Bone Miner Metab 19:115–118PubMedCrossRefGoogle Scholar
  13. 13.
    Van der Klift M, De Laet CE, McCloskey EV, Hofman A, Pols HA (2002) The incidence of vertebral fractures in men and women: the Rotterdam Study. J Bone Miner Res 17:1051–1056PubMedCrossRefGoogle Scholar
  14. 14.
    The European Prospective Osteoporosis Study (EPOS) Group (2002) Incidence of vertebral fracture in Europe: results from the European Prospective Osteoporosis Study (EPOS). J Bone Miner Res 17:716–724CrossRefGoogle Scholar
  15. 15.
    Kwok AW, Leung JC, Chan AY, Au BS, Lau EM, Yurianto H, Yuktanandana P, Yoshimura N, Muraki S, Oka H, Akune T, Leung PC (2012) Prevalence of vertebral fracture in Asian men and women: comparison between Hong Kong, Thailand, Indonesia and Japan. Public health 126:523–531PubMedCrossRefGoogle Scholar
  16. 16.
    Bow CH, Cheung E, Cheung CL, Xiao SM, Loong C, Soong C, Tan KC, Luckey MM, Cauley JA, Fujiwara S, Kung AW (2011) Ethnic difference of clinical vertebral fracture risk. Osteoporos IntGoogle Scholar
  17. 17.
    Matsumoto T, Hagino H, Shiraki M, Fukunaga M, Nakano T, Takaoka K, Morii H, Ohashi Y, Nakamura T (2009) Effect of daily oral minodronate on vertebral fractures in Japanese postmenopausal women with established osteoporosis: a randomized placebo-controlled double-blind study. Osteoporos Int 20:1429–1437PubMedCrossRefGoogle Scholar
  18. 18.
    Okazaki R, Hagino H, Ito M, Sone T, Nakamura T, Mizunuma H, Fukunaga M, Shiraki M, Nishizawa Y, Ohashi Y, Matsumoto T (2012) Efficacy and safety of monthly oral minodronate in patients with involutional osteoporosis. Osteoporos Int 23:1737–1745PubMedCrossRefGoogle Scholar
  19. 19.
    Orimo H, Hayashi Y, Fukunaga M, Sone T, Fujiwara S, Shiraki M, Kushida K, Miyamoto S, Soen S, Nishimura J, Oh-Hashi Y, Hosoi T, Gorai I, Tanaka H, Igai T, Kishimoto H (2001) Diagnostic criteria for primary osteoporosis: year 2000 revision. J Bone Miner Metab 19:331–337PubMedCrossRefGoogle Scholar
  20. 20.
    Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, Chesnut CH 3rd, Brown J, Eriksen EF, Hoseyni MS, Axelrod DW, Miller PD (1999) Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 282:1344–1352PubMedCrossRefGoogle Scholar
  21. 21.
    Wu CY, Li J, Jergas M, Genant HK (1995) Comparison of semiquantitative and quantitative techniques for the assessment of prevalent and incident vertebral fractures. Osteoporos Int 5:354–370PubMedCrossRefGoogle Scholar
  22. 22.
    Genant HK, Wu CY, van Kuijk C, Nevitt MC (1993) Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res 8:1137–1148PubMedCrossRefGoogle Scholar
  23. 23.
    Hagino H, Shiraki M, Fukunaga M, Nakano T, Takaoka K, Ohashi Y, Nakamura T, Matsumoto T (2012) Three years of treatment with minodronate in patients with postmenopausal osteoporosis. J Bone Miner Metab 30:439–446PubMedCrossRefGoogle Scholar
  24. 24.
    Nakamura T, Sugimoto T, Nakano T, Kishimoto H, Ito M, Fukunaga M, Hagino H, Sone T, Yoshikawa H, Nishizawa Y, Fujita T, Shiraki M (2012) Randomized Teriparatide [Human Parathyroid Hormone (PTH) 1–34] Once-Weekly Efficacy Research (TOWER) Trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk. J Clin Endocrinol Metab 97:3097–3106PubMedCrossRefGoogle Scholar
  25. 25.
    Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348:1535–1541PubMedCrossRefGoogle Scholar
  26. 26.
    Black DM, Delmas PD, Eastell R, Reid IR, Boonen S et al (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356:1809–1822PubMedCrossRefGoogle Scholar
  27. 27.
    Ruyssen-Witrand A, Gossec L, Kolta S, Dougados M, Roux C (2007) Vertebral dimensions as risk factor of vertebral fracture in osteoporotic patients: a systematic literature review. Osteoporos IntGoogle Scholar
  28. 28.
    Ebetino FH, Hogan AM, Sun S, Tsoumpra MK, Duan X, Triffitt JT, Kwaasi AA, Dunford JE, Barnett BL, Oppermann U, Lundy MW, Boyde A, Kashemirov BA, McKenna CE, Russell RG (2011) The relationship between the chemistry and biological activity of the bisphosphonates. Bone 49:20–33PubMedCrossRefGoogle Scholar
  29. 29.
    Hagino H, Nishizawa Y, Sone T, Morii H, Taketani Y, Nakamura T, Itabashi A, Mizunuma H, Ohashi Y, Shiraki M, Minamide T, Matsumoto T (2009) A double-blinded head-to-head trial of minodronate and alendronate in women with postmenopausal osteoporosis. Bone 44:1078–1084PubMedCrossRefGoogle Scholar
  30. 30.
    Hagino H (2009) Review of the preventive effect of minodronic acid on fracture in Japanese patients with osteoporosis (in Japanese). Clinical Calcium 19:75–84PubMedGoogle Scholar

Copyright information

© The Japanese Society for Bone and Mineral Research and Springer Japan 2013

Authors and Affiliations

  • Hiroshi Hagino
    • 1
  • Masataka Shiraki
    • 2
  • Masao Fukunaga
    • 3
  • Tetsuo Nakano
    • 4
  • Kunio Takaoka
    • 5
  • Yasuo Ohashi
    • 6
  • Toshitaka Nakamura
    • 7
  • Toshio Matsumoto
    • 8
  1. 1.School of Health ScienceTottori University Faculty of MedicineTottoriJapan
  2. 2.Research Institute and Practice for Involutional DiseasesNaganoJapan
  3. 3.Kawasaki Medical SchoolOkayamaJapan
  4. 4.Tamana Central HospitalKumamotoJapan
  5. 5.Hanwa Joint Reconstruction Center HospitalOsakaJapan
  6. 6.Department of Biostatistics, School of Public HealthUniversity of TokyoTokyoJapan
  7. 7.Department of Orthopedic SurgeryUniversity of Occupational and Environmental HealthFukuokaJapan
  8. 8.Department of Medicine and Bioregulatory SciencesUniversity of Tokushima Graduate School of Medical ScienceTokushimaJapan

Personalised recommendations